BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare ConferenceGlobeNewsWire • 04/27/23
BridgeBio Pharma (BBIO) Moves 9.7% Higher: Will This Strength Last?Zacks Investment Research • 03/27/23
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb's OPDIVO® (nivolumab)GlobeNewsWire • 03/23/23
BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)GlobeNewsWire • 03/21/23
BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)GlobeNewsWire • 03/17/23
Is BridgeBio Pharma (BBIO) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 03/10/23
BridgeBio Pharma shares soar 55% on positive achondroplasia trial resultsProactive Investors • 03/06/23
BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism StudyInvestors Business Daily • 03/06/23
BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023GlobeNewsWire • 03/03/23
Does BridgeBio Pharma (BBIO) Have the Potential to Rally 67.36% as Wall Street Analysts Expect?Zacks Investment Research • 02/28/23
BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business UpdateGlobeNewsWire • 02/23/23
Will BridgeBio Pharma (BBIO) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research • 02/16/23
BridgeBio: If Acoramidis Completes Comeback, This Highly Prized Biotech's Share Price Should SoarSeeking Alpha • 02/15/23
BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023GlobeNewsWire • 02/13/23